Minerva (NERV) Stock Price Soars After $200 Million Funding Deal

The Minerva (NERV) stock price made headlines after skyrocketing more than 130% in a single day, marking one of the biggest rallies in the biotech sector this year. 

Shares of Minerva Neurosciences (NASDAQ: NERV) surged to $6.41, closing 140% higher than the previous day, after the company revealed it had secured up to $200 million in funding to advance its experimental schizophrenia drug, roluperidone. 

This major financial boost has reignited investor confidence and positioned Minerva back in the spotlight as a promising player in neuropsychiatric treatment development. Read this article to find out more!

Minerva Neurosciences (NERV) Journey

Minerva Neurosciences (NERV) has long been focused on developing innovative treatments for schizophrenia, especially targeting negative symptoms, one of the most challenging aspects of the disorder. 

The company’s latest financing agreement represents a turning point after years of volatility and uncertainty. According to the official announcement, Minerva signed a securities purchase agreement with a group of institutional investors to secure up to $200 million in total funding. 

The deal includes $80 million in upfront capital, with an additional $80 million available through Tranche A warrants and another $40 million through Tranche B warrants, depending on certain milestones.

This structured funding model allows Minerva to maintain flexibility while ensuring a steady flow of capital as it progresses through key clinical and regulatory milestones.

Read Also: Glottis Share Price: Performance and Market Sentiment

Minerva: Schizophrenia Drug Development

The new funding will primarily support the Phase 3 confirmatory trial of roluperidone, a potential breakthrough treatment for the negative symptoms of schizophrenia, such as emotional flatness, lack of motivation, and social withdrawal.

Earlier this year, Minerva received confirmation from the U.S. Food and Drug Administration (FDA) regarding the design of this pivotal trial. 

The Phase 3 study will evaluate a 64 mg dose of roluperidone in a randomized, double-blind, placebo-controlled format, with the primary goal being improvement in the PANSS Marder negative symptoms factor score over 12 weeks.

If successful, the trial could pave the way for an FDA approval and mark a major step forward for patients struggling with schizophrenia symptoms that current medications fail to treat effectively.

Read Also: EchoStar (SATS) Stock Price Predictions 2025–2030 

Leadership and Scientific Restructuring

As part of the financing deal, Minerva announced plans to restructure its leadership team and add up to three new board members with expertise in psychiatry and clinical research. 

The company will also establish a Scientific Advisory Board composed of leading experts in neuroscience and psychopharmacology.

These changes aim to strengthen Minerva’s scientific and operational direction as it moves closer to the final stages of drug development.

Market Reaction: Minerva (NERV) Stock Price Today

Investors reacted strongly to the announcement. The NERV stock price surged from around $2.66 to over $12.46 intraday before closing at $6.41, a gain of nearly 141%, one of the most dramatic single-day increases in the company’s history.

This surge was driven by optimism surrounding the new funding, which not only secures the company’s financial future but also signals growing institutional confidence. 

The private placement was led by Vivo Capital, with participation from Janus Henderson and Federated Hermes Kaufmann Funds, major names in biotech investing.

The total market capitalization of Minerva rose to $44.83 million, reflecting renewed confidence that the company could soon deliver meaningful clinical results.

Read Also: Tempus AI Stock, Considering the Investment Potential

Future Holds for Minerva (NERV) Stock 

If the upcoming Phase 3 trial yields positive results, Minerva could quickly transition from a small clinical-stage company to a leading name in psychiatric drug innovation. 

The funding also provides room for preparing an FDA New Drug Application (NDA) and laying the foundation for a potential commercial launch.

Market analysts remain cautiously optimistic. While the recent price surge reflects excitement, they note that biotech stocks are often volatile, especially when tied to trial results. 

Still, Minerva’s clear regulatory pathway and robust financing give it a solid chance to make significant progress in 2025.

Read Also: DJT Stock Company Profile and Today’s Price

Conclusion

The Minerva (NERV) stock price rally highlights how strategic financing and scientific milestones can dramatically shift investor sentiment in the biotech sector. 

With up to $200 million secured, Minerva Neurosciences is now well-positioned to advance its roluperidone program and potentially deliver a groundbreaking treatment for schizophrenia. 

Whether this momentum will continue depends on the success of the upcoming Phase 3 trial, but for now, Minerva has captured both investor attention and renewed hope for patients worldwide.

Explore expert insights, in-depth articles, and the latest crypto market trends on Bitrue blog. Whether you're a beginner or a seasoned trader, there's something valuable for everyone. Stay informed and ahead in your crypto journey. Register now on Bitrue and take the next step!

FAQ

What caused Minerva (NERV) stock price to rise?

The surge came after Minerva announced a $200 million funding deal to support its Phase 3 schizophrenia drug trial.

What does Minerva Neurosciences do?

Minerva is a biopharmaceutical company developing treatments for neuropsychiatric disorders, particularly schizophrenia.

How much did NERV stock rise?

The stock jumped around 141% in one day, reaching highs near $12.46 before closing at $6.41.

What is roluperidone?

Roluperidone is Minerva’s lead drug candidate designed to treat the negative symptoms of schizophrenia, such as lack of motivation and emotional flatness.

Is Minerva a good investment right now?

While the company’s funding and clinical progress are positive signs, investors should consider the inherent risks of biotech stocks, which depend heavily on clinical trial outcomes.